Cantor Fitzgerald Reiterates Neutral on Regeneron Pharmaceuticals, Maintains $815 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Alethia Young reiterated a Neutral rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and maintained an $815 price target.
June 23, 2023 | 3:57 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cantor Fitzgerald analyst Alethia Young reiterated a Neutral rating on Regeneron Pharmaceuticals and maintained an $815 price target.
The news of Cantor Fitzgerald reiterating a Neutral rating on Regeneron Pharmaceuticals and maintaining an $815 price target is directly related to REGN. However, as it is a reiteration of the existing rating and price target, it is unlikely to have a significant short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100